<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age/><report-id>US-PFIZER INC-2013031974</report-id><gender>female</gender><reactions><reaction>rash on her skin</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>Accupril</drug-name><manufacturer/><ingredients/></drug></drugs><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>psur</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4254121_P31</messagenumb>
		<messagesenderidentifier>PFIZERINC</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151550</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>US-PFIZER INC-2013031974</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2013-01-23</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-23</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-PFIZER INC-2013031974</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>PFIZERINC</senderorganization>
			<senderfamilyname>Head Drug Safety Surveillance</senderfamilyname>
			<senderstreetaddress>150 East 42nd Street</senderstreetaddress>
			<sendercity>New York</sendercity>
			<senderstate>New York</senderstate>
			<senderpostcode>10017</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2127335544</sendertel>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20785</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3019183134</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientsex code="2">Female</patientsex>
			<patientpastdrugtherapy>
				<patientdrugname>QUINAPRIL</patientdrugname>
				<patientdrgreactionmeddraversion>15.1</patientdrgreactionmeddraversion>
				<patientdrugreaction>Drug allergy</patientdrugreaction>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>rash on her skin</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Skin rash</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Rash</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>Accupril</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>19-885</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugstructuredosagenumb>5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>5 mg, UNK</drugdosagetext>
				<drugdosageform normalized="film-coated tablet">Film-coated tablet</drugdosageform>
				<actiondrug code="5">Unknown</actiondrug>
				<activesubstance>
					<activesubstancename>QUINAPRIL HCL</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Skin rash</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Skin rash</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a spontaneous report from a contactable consumer. This female patient of an unspecified age and ethnicity started to receive <Semaphore x="1115820" class="Medicine" value="quinapril" score="0.93" ID="258204">quinapril </Semaphore>hcl (<Semaphore x="17396" class="Medicine" value="Accupril" score="0.49" ID="281261">ACCUPRIL</Semaphore>) via an unspecified route of administration from an unspecified date at 5 mg for an unspecified indication. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient previously took generic <Semaphore x="1115820" class="Medicine" value="quinapril" score="0.93" ID="258204">quinapril</Semaphore>. The patient reported that she <Semaphore x="2003795" class="Procedure" value="Have Allergy" score="1.00" ID="C113411">had <Semaphore x="3017953" class="MedDRA LLT" value="Hypersensitivity" score="1.00" ID="10020751">allergies </Semaphore></Semaphore>to the excipients in the generic <Semaphore x="1115820" class="Medicine" value="quinapril" score="0.93" ID="258204">quinapril </Semaphore>and therefore took Pfizer brand. However, when she changed to Pfizer brand, the patient experienced <Semaphore x="2527042" class="Disease or Finding" value="Skin Rash" score="1.00" ID="C39594">rash on her skin </Semaphore>on an unspecified date. The action taken in <Semaphore x="1854566" class="Disease or Finding" value="Disease Response" score="1.00" ID="C50995">response </Semaphore>to the event for <Semaphore x="1115820" class="Medicine" value="quinapril" score="0.93" ID="258204">quinapril </Semaphore>hcl was unknown. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event was unknown. Patient was unsure whether it was due to the medication however believed it might be <Semaphore x="2958863" class="MedDRA LLT" value="Food allergy" score="1.00" ID="10016946">food <Semaphore x="1470824" class="Disease or Finding" value="Allergic Reaction" score="1.00" ID="C114476">allergies</Semaphore></Semaphore>.</narrativeincludeclinical>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>